CalbaTech, Inc.'s Subsidiary, LifeStem Inc., Selects Leading Physician As Chief Medical Officer

IRVINE, Calif., Nov. 22 /PRNewswire-FirstCall/ -- CalbaTech, Inc. , an emerging life sciences company ( concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, announced today that its wholly owned subsidiary LifeStem, Inc., has selected Dr. Jason R. Van Tassel as its Chief Medical Officer.

Los Angeles based physician, Dr. Jason R. Van Tassel M.D., was selected to become LifeStem's Chief Medical Officer. In this new position, Dr. Van Tassel will direct all of the company's medical technologies related to its Stem Cell MicroBank service and provide advisory, consulting and technical services to the company. He will also be directly involved in the rollout of LifeStem's MicroBanking Stem Cell collection and storage service with Solana MedSpas which the company announced on November 17th.

"We're very fortunate to have Dr. Van Tassel as part of our management team," said LifeStem President Dan Fulkerson. "Dr. Van Tassel has been with our parent company, CalbaTech, as an advisory board member for the past year so he knows our business and as is well qualified to fill this important role," Mr. Fulkerson added.

According to Dr. Van Tassel, the timing of his appointment was ideal. "The stem cell market is quickly expanding and the benefits of adult stem cells as a regenerative therapy are rapidly becoming evident. With the addition of the Solana MedSpa network, I am convinced that LifeStem's MicroBank service will be an essential component to an overall stem cell therapy."

Dr. Van Tassel is currently in medical practice specializing in Otolaryngology, Facial Plastic and Reconstructive Surgery in Los Angeles, CA. Dr. Van Tassel attended Georgetown University School of Medicine in Washington D.C., graduating with Honors in 1997. Upon completion of his residency, Dr. Van Tassel joined the faculty at the University of California at Irvine in the Department of Facial Plastic and Reconstructive Surgery, completing a fellowship in 2003. He is currently board certified in Otolaryngology and board eligible in Facial Plastic and Reconstructive Surgery. He is an Associate Clinical Professor at UCLA in the Department of Surgery, in the Division of Otolaryngology Head and Neck Surgery. Prior to practicing medicine in Los Angeles, Dr. Van Tassel worked at Hybritech Inc., a subsidiary of Eli Lilly, where he performed research investigating manufacturing processes related to monoclonal antibody test assays. In addition, Dr. Van Tassel also investigated retinal signal transduction pathways for the Dept. of Neurosciences at San Diego State University.

About CalbaTech

CalbaTech, Inc. is an emerging life sciences company ( concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.

About LifeStem

LifeStem, a wholly owned subsidiary of CalbaTech, is positioning itself to become a leading supplier of "Cellular Logistics." The Company's focus is to provide services and technologies to facilitate the efficient acquisition and delivery of adult stem cells, development of stem cell delivery devices for clinical applications and clinical applications of specific stem cell based therapies. LifeStem, in addition to being the first company to offer micro collection of stem cells, is also the first company to offer a collection service that collects and stores two different types of stem cells. The Company has filed patent applications for an endoscopic stem cell delivery device, developed by Dr. Van Tassel, and its novel Stem Cell MicroBank service.

Contact: Paul Knopick E&E Communications (949) 707-5365

Note: Certain statements in this news release may contain "forward looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, may include forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will be accurate and actual results and future events could differ materially from those anticipated in such statements.

CalbaTech, Inc.

CONTACT: Paul Knopick of E&E Communications, +1-949-707-5365,, for CalbaTech, Inc.

Back to news